Literature DB >> 34085743

European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force-Second revision.

Peter Y K Van den Bergh1, Pieter A van Doorn2, Robert D M Hadden3, Bert Avau4, Patrik Vankrunkelsven5, Jeffrey A Allen6, Shahram Attarian7, Patricia H Blomkwist-Markens8, David R Cornblath9, Filip Eftimov10, H Stephan Goedee11, Thomas Harbo12, Satoshi Kuwabara13, Richard A Lewis14, Michael P Lunn15, Eduardo Nobile-Orazio16, Luis Querol17, Yusuf A Rajabally18, Claudia Sommer19, Haluk A Topaloglu20.   

Abstract

To revise the 2010 consensus guideline on chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Seventeen disease experts, a patient representative, and two Cochrane methodologists constructed 12 Population/Intervention/Comparison/Outcome (PICO) questions regarding diagnosis and treatment to guide the literature search. Data were extracted and summarized in GRADE summary of findings (for treatment PICOs) or evidence tables (for diagnostic PICOs). Statements were prepared according to the GRADE Evidence-to-Decision frameworks. Typical CIDP and CIDP variants were distinguished. The previous term "atypical CIDP" was replaced by "CIDP variants" because these are well characterized entities (multifocal, focal, distal, motor, or sensory CIDP). The levels of diagnostic certainty were reduced from three (definite, probable, possible CIDP) to only two (CIDP and possible CIDP), because the diagnostic accuracy of criteria for probable and definite CIDP did not significantly differ. Good Practice Points were formulated for supportive criteria and investigations to be considered to diagnose CIDP. The principal treatment recommendations were: (a) intravenous immunoglobulin (IVIg) or corticosteroids are strongly recommended as initial treatment in typical CIDP and CIDP variants; (b) plasma exchange is strongly recommended if IVIg and corticosteroids are ineffective; (c) IVIg should be considered as first-line treatment in motor CIDP (Good Practice Point); (d) for maintenance treatment, IVIg, subcutaneous immunoglobulin or corticosteroids are recommended; (e) if the maintenance dose of any of these is high, consider either combination treatments or adding an immunosuppressant or immunomodulatory drug (Good Practice Point); and (f) if pain is present, consider drugs against neuropathic pain and multidisciplinary management (Good Practice Point).
© 2021 European Academy of Neurology and Peripheral Nerve Society.

Entities:  

Keywords:  CIDP; GRADE; diagnosis; guideline; treatment

Mesh:

Substances:

Year:  2021        PMID: 34085743     DOI: 10.1111/jns.12455

Source DB:  PubMed          Journal:  J Peripher Nerv Syst        ISSN: 1085-9489            Impact factor:   3.494


  20 in total

1.  COVID-19 and MOG-IgG-associated acquired demyelinating polyneuropathy compatible with chronic inflammatory demyelinating polyneuropathy in a previously healthy girl.

Authors:  Asra Akbar; Gregory M Blume; Sean Creeden; Sharjeel Ahmad
Journal:  Proc (Bayl Univ Med Cent)       Date:  2022-06-17

2.  A Rare Case of COVID-19-Induced Chronic Demyelinating Polyneuropathy.

Authors:  Dhaval Patel; Gaurav Mandal; Lawrence Chukwueke; Kenneth Woods
Journal:  Cureus       Date:  2022-05-20

3.  Tacrolimus Combined with Corticosteroids Improved the Outcome of CIDP Patients with Autoantibodies Against Paranodal Proteins.

Authors:  Meng-Ge Yang; Li Xu; Suqiong Ji; Huajie Gao; Qing Zhang; Bitao Bu
Journal:  Neuropsychiatr Dis Treat       Date:  2022-06-16       Impact factor: 2.989

4.  Revisiting the spectrum of IgM-related neuropathies in a large cohort of IgM monoclonal gammopathy.

Authors:  Benjamin Bardel; Valérie Molinier-Frenkel; Fabien Le Bras; Samar S Ayache; Tarik Nordine; Jean-Pascal Lefaucheur; Violaine Planté-Bordeneuve
Journal:  J Neurol       Date:  2022-05-03       Impact factor: 6.682

5.  Acute-onset polyradiculoneuropathy after SARS-CoV2 vaccine in the West and North Midlands, United Kingdom.

Authors:  Lay Khoon Loo; Omar Salim; Di Liang; Aimee Goel; Salini Sumangala; Ashwin S Gowda; Brendan Davies; Yusuf A Rajabally
Journal:  Muscle Nerve       Date:  2021-11-26       Impact factor: 3.852

6.  Pearls & Oy-sters: Bilateral Mononeuropathic Neuralgic Amyotrophy Triggered by Bartonella henselae Infection Responsive to Immunoglobulin.

Authors:  Anelia Dietmann; Eugénie Colin-Benoit; Gerd Tinkhauser; Thomas Raphael Meinel; Olivier Scheidegger
Journal:  Neurology       Date:  2022-02-10       Impact factor: 9.910

7.  Diabetes Mellitus Is a Possible Risk Factor for Nodo-paranodopathy With Antiparanodal Autoantibodies.

Authors:  Luise Appeltshauser; Julia Messinger; Katharina Starz; David Heinrich; Anna-Michelle Brunder; Helena Stengel; Bianca Fiebig; Ilya Ayzenberg; Frank Birklein; Christian Dresel; Johannes Dorst; Florian Dvorak; Alexander Grimm; Alexander Joerk; Frank Leypoldt; Mathias Mäurer; Patrick Merl; Sebastian Michels; Kalliopi Pitarokoili; Mathias Rosenfeldt; Anne-Dorte Sperfeld; Marc Weihrauch; Gabriel Simon Welte; Claudia Sommer; Kathrin Doppler
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2022-03-21

8.  Two CIDP Variants Patients With Anti-Caspr1 Antibodies in South China.

Authors:  Chong Li; Hui Zheng; Chao Yuan; Yanran Li; Yafang Hu; Haishan Jiang
Journal:  Front Immunol       Date:  2022-03-11       Impact factor: 7.561

9.  Motor Nerve Conduction Block Estimation in Demyelinating Neuropathies by Deconvolution.

Authors:  Luca Mesin; Edoardo Lingua; Dario Cocito
Journal:  Bioengineering (Basel)       Date:  2022-01-10

10.  Clinical and Laboratory Features in Anti-NF155 Autoimmune Nodopathy.

Authors:  Lorena Martín-Aguilar; Cinta Lleixà; Elba Pascual-Goñi; Marta Caballero-Ávila; Laura Martínez-Martínez; Jordi Díaz-Manera; Ricard Rojas-García; Elena Cortés-Vicente; Janina Turon-Sans; Noemi de Luna; Xavier Suárez-Calvet; Eduard Gallardo; Yusuf Rajabally; Sangeeta Scotton; Bart C Jacobs; Adája Baars; Andrea Cortese; Elisa Vegezzi; Romana Höftberger; Fritz Zimprich; Cornelia Roesler; Eduardo Nobile-Orazio; Giuseppe Liberatore; Fu Liong Hiew; Alicia Martínez-Piñeiro; Alejandra Carvajal; Raquel Piñar-Morales; Mercedes Usón-Martín; Olalla Albertí; Maria Ángeles López-Pérez; Fabian Márquez; Julio Pardo-Fernández; Laura Muñoz-Delgado; Macarena Cabrera-Serrano; Nicolau Ortiz; Manuel Bartolomé; Özgür Duman; Vera Bril; Darwin Segura-Chávez; Kalliopi Pitarokoili; Claudia Steen; Isabel Illa; Luis Querol
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2021-11-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.